{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:06:53Z","timestamp":1789024013219,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"DOI":"10.7759\/cureus.116027","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:31:17Z","timestamp":1789021877000},"source":"Crossref","is-referenced-by-count":0,"title":["Haemophagocytic Lymphohistiocytosis Triggered by Visceral Leishmaniasis Masquerading as Epstein-Barr Virus (EBV)-Associated Haemophagocytic Lymphohistiocytosis in Rheumatoid Arthritis: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Frederik","family":"Fleurinck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbet","family":"Henckaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00eblle","family":"Beckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eef","family":"Vanerwegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Verschueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2314005","article-title":"Hemophagocytic lymphohistiocytosis","volume":"392","author":"Henter JI","year":"2025","unstructured":"Henter JI. Hemophagocytic lymphohistiocytosis. N Engl J Med. 2025, 392:584-98. 10.1056\/NEJMra2314005","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.07.004","article-title":"Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies","volume":"45","author":"Brito-Zer\u00f3n P","year":"2016","unstructured":"Brito-Zer\u00f3n P, Bosch X, P\u00e9rez-de-Lis M, et al.. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. Semin Arthritis Rheum. 2016, 45:391-9. 10.1016\/j.semarthrit.2015.07.004","journal-title":"Semin Arthritis Rheum"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.17605\/OSF.IO\/5GY3E","article-title":"Hemophagocytic lymphohistiocytosis in patients with inflammatory bowel diseases: a scoping review","author":"Lan T","year":"2025","unstructured":"Lan T. Hemophagocytic lymphohistiocytosis in patients with inflammatory bowel diseases: a scoping review. 2025, 10.17605\/OSF.IO\/5GY3E"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06252-z","article-title":"Hemophagocytic lymphohistiocytosis occurring in inflammatory bowel disease: systematic review","volume":"66","author":"Coburn ES","year":"2021","unstructured":"Coburn ES, Siegel CA, Winter M, Shah ED. Hemophagocytic lymphohistiocytosis occurring in inflammatory bowel disease: systematic review. Dig Dis Sci. 2021, 66:843-54. 10.1007\/s10620-020-06252-z","journal-title":"Dig Dis Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2018.1533035","article-title":"Haemophagocytic lymphohistiocytosis associated with leishmaniasis reactivation: a potential adverse event to anti-tumour necrosis factor-\u03b1 therapy","volume":"48","author":"Bukan KB","year":"2019","unstructured":"Bukan KB, Nardo-Marino A, Hagdrup C, et al.. Haemophagocytic lymphohistiocytosis associated with leishmaniasis reactivation: a potential adverse event to anti-tumour necrosis factor-\u03b1 therapy. Scand J Rheumatol. 2019, 48:342-3. 10.1080\/03009742.2018.1533035","journal-title":"Scand J Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw670","article-title":"Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)","volume":"63","author":"Aronson N","year":"2016","unstructured":"Aronson N, Herwaldt BL, Libman M, et al.. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016, 63:e202-64. 10.1093\/cid\/ciw670","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.crpvbd.2026.100377","article-title":"Revisiting visceral leishmaniasis in immunocompromised patients: ongoing gaps and advances in diagnostics, therapies, and preventive measures","volume":"9","author":"Partovi Moghaddam S","year":"2026","unstructured":"Partovi Moghaddam S, Sharifi I, Lotfalizadeh N, et al.. Revisiting visceral leishmaniasis in immunocompromised patients: ongoing gaps and advances in diagnostics, therapies, and preventive measures. Curr Res Parasitol Vector Borne Dis. 2026, 9:100377. 10.1016\/j.crpvbd.2026.100377","journal-title":"Curr Res Parasitol Vector Borne Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.70104","article-title":"Hemophagocytic lymphohistiocytosis in visceral leishmaniasis: a rare yet treatable complication","volume":"16","author":"Varshney A","year":"2024","unstructured":"Varshney A, Solanki R, Manna D, Rodriguez E, Bindra VK. Hemophagocytic lymphohistiocytosis in visceral leishmaniasis: a rare yet treatable complication. Cureus. 2024, 16:e70104. 10.7759\/cureus.70104","journal-title":"Cureus"},{"key":"ref9","article-title":"Epidemiologische surveillance van leishmaniasis Leishmania spp","author":"Hermy MRG","year":"2024","unstructured":"Hermy MRG, Van Esbroeck M. Epidemiologische surveillance van leishmaniasis Leishmania spp. Brussels: Sciensano; Referentielaboratorium voor Leishmania spp., Instituut voor Tropische Geneeskunde. 2024,","journal-title":"Brussels: Sciensano; Referentielaboratorium voor Leishmania spp., Instituut voor Tropische Geneeskunde"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S388880","article-title":"Hemophagocytic lymphohistiocytosis in adults: a retrospective study in a Belgian teaching hospital","volume":"15","author":"Yildiz H","year":"2022","unstructured":"Yildiz H, Castanares-Zapatero D, d'Abadie P, Bailly S, Yombi JC. Hemophagocytic lymphohistiocytosis in adults: a retrospective study in a Belgian teaching hospital. Int J Gen Med. 2022, 15:8111-20. 10.2147\/IJGM.S388880","journal-title":"Int J Gen Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12556","article-title":"Leishmaniasis in immunosuppressed individuals","volume":"20","author":"van Griensven J","year":"2014","unstructured":"van Griensven J, Carrillo E, L\u00f3pez-V\u00e9lez R, Lynen L, Moreno J. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect. 2014, 20:286-99. 10.1111\/1469-0691.12556","journal-title":"Clin Microbiol Infect"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2019.18178","article-title":"Remembering visceral leishmaniasis as a potential trigger of haemophagocytic lymphohistiocytosis in individuals treated with anti-TNF-alpha therapy","volume":"6","author":"Nardo-Marino A","year":"2019","unstructured":"Nardo-Marino A, Bukan K, Nielsen HV, El Fassi D. Remembering visceral leishmaniasis as a potential trigger of haemophagocytic lymphohistiocytosis in individuals treated with anti-TNF-alpha therapy. Eur J Rheumatol. 2019, 6:226-7. 10.5152\/eurjrheum.2019.18178","journal-title":"Eur J Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19118","article-title":"Haemophagocytic lymphohistiocytosis due to leishmaniasis following anti-tumour necrosis factor-alpha therapy","volume":"203","author":"Estabrooks KL","year":"2023","unstructured":"Estabrooks KL, De Silva K, Survela L, Stevenson WS. Haemophagocytic lymphohistiocytosis due to leishmaniasis following anti-tumour necrosis factor-alpha therapy. Br J Haematol. 2023, 203:497-8. 10.1111\/bjh.19118","journal-title":"Br J Haematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel235","article-title":"Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab","volume":"45","author":"Bassetti M","year":"2006","unstructured":"Bassetti M, Pizzorni C, Gradoni L, Del Bono V, Cutolo M, Viscoli C. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology. 2006, 45:1446-8. 10.1093\/rheumatology\/kel235","journal-title":"Rheumatology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000370238","article-title":"Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: case report and review of the literature","volume":"230","author":"Catal\u00e0 A","year":"2015","unstructured":"Catal\u00e0 A, Ro\u00e9 E, Dalmau J, Pomar V, Mu\u00f1oz C, Yelamos O, Puig L. Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: case report and review of the literature. Dermatology. 2015, 230:204-7. 10.1159\/000370238","journal-title":"Dermatology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.reumae.2017.07.014","article-title":"Visceral leishmaniasis in a patient with rheumatoid arthritis treated with methotrexate","volume":"15","author":"Loarce-Martos J","year":"2019","unstructured":"Loarce-Martos J, Garrote-Corral S, Gioia F, Bachiller-Corral J. Visceral leishmaniasis in a patient with rheumatoid arthritis treated with methotrexate. Reumatol Cl\u00ednica Engl Ed. 2019, 15:130-2. 10.1016\/j.reumae.2017.07.014","journal-title":"Reumatol Cl\u00ednica Engl Ed"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.01.011","article-title":"Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab","volume":"77","author":"Molt\u00f3 A","year":"2010","unstructured":"Molt\u00f3 A, Mateo L, Lloveras N, Oliv\u00e9 A, Minguez S. Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab. Joint Bone Spine. 2010, 77:271-3. 10.1016\/j.jbspin.2010.01.011","journal-title":"Joint Bone Spine"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0775-y","article-title":"Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?","volume":"27","author":"Tektonidou MG","year":"2008","unstructured":"Tektonidou MG, Skopouli FN. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?. Clin Rheumatol. 2008, 27:541-2. 10.1007\/s10067-007-0775-y","journal-title":"Clin Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2017.16066","article-title":"Visceral leishmaniasis in a patient with rheumatoid arthritis undergoing treatment with methotrexate: case report and review of the literature","volume":"4","author":"Trigkidis K","year":"2017","unstructured":"Trigkidis K, Geladari E, Kokkinakis E, Vallianou N. Visceral leishmaniasis in a patient with rheumatoid arthritis undergoing treatment with methotrexate: case report and review of the literature. Eur J Rheumatol. 2017, 4:139-41. 10.5152\/eurjrheum.2017.16066","journal-title":"Eur J Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2008.09.012","article-title":"Visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate","volume":"13","author":"Venizelos I","year":"2009","unstructured":"Venizelos I, Tatsiou Z, Papathomas TG, Orazi A. Visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate. Int J Infect Dis. 2009, 13:e169-72. 10.1016\/j.ijid.2008.09.012","journal-title":"Int J Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-016-0527-1","article-title":"Cutaneous and visceral leishmaniasis during anti-TNF\u03b1 therapy","volume":"167","author":"Guarneri C","year":"2017","unstructured":"Guarneri C, Bevelacqua V, Patterson JW, Tchernev G. Cutaneous and visceral leishmaniasis during anti-TNF\u03b1 therapy. Wien Med Wochenschr. 2017, 167:78-82. 10.1007\/s10354-016-0527-1","journal-title":"Wien Med Wochenschr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/reports9010029","article-title":"Case reports of visceral leishmaniasis-associated hemophagocytic lymphohistiocytosis in adults: a complex immune phenomenon","volume":"9","author":"Bougiouklou T","year":"2026","unstructured":"Bougiouklou T, Petrakis V, Dragoumani I, Gouveri E, Papazoglou D. Case reports of visceral leishmaniasis-associated hemophagocytic lymphohistiocytosis in adults: a complex immune phenomenon. Reports. 2026, 9:29. 10.3390\/reports9010029","journal-title":"Reports"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90129-D","article-title":"Leishmaniasis acquired in Belgium","volume":"338","author":"Cohen C","year":"1991","unstructured":"Cohen C. Leishmaniasis acquired in Belgium. Lancet. 1991, 338:128. 10.1016\/0140-6736(91)90129-D","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter JI","year":"2007","unstructured":"Henter JI, Horne A, Aric\u00f3 M, et al.. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007, 48:124-31. 10.1002\/pbc.21039","journal-title":"Pediatr Blood Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025077","article-title":"Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited","volume":"144","author":"Henter JI","year":"2024","unstructured":"Henter JI, Sieni E, Eriksson J, et al.. Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited. Blood. 2024, 144:2308-18. 10.1182\/blood.2024025077","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet L","year":"2014","unstructured":"Fardet L, Galicier L, Lambotte O, et al.. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014, 66:2613-20. 10.1002\/art.38690","journal-title":"Arthritis Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12386","article-title":"Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens","volume":"162","author":"Chellapandian D","year":"2013","unstructured":"Chellapandian D, Das R, Zelley K, Wiener SJ, Zhao H, Teachey DT, Nichols KE. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013, 162:376-82. 10.1111\/bjh.12386","journal-title":"Br J Haematol"},{"key":"ref28","article-title":"Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab","volume":"23","author":"Fabre S","year":"2006","unstructured":"Fabre S, Gibert C, Lechiche C, et al.. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin Exp Rheumatol. 2006, 23:891-2.","journal-title":"Clin Exp Rheumatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0356-5","article-title":"Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept","volume":"26","author":"Bagalas V","year":"2007","unstructured":"Bagalas V, Kioumis I, Argyropoulou P, Patakas D. Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin Rheumatol. 2007, 26:1344-5. 10.1007\/s10067-006-0356-5","journal-title":"Clin Rheumatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181c8aa33","article-title":"An atypical presentation of visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with infliximab","volume":"16","author":"Kritikos K","year":"2010","unstructured":"Kritikos K, Haritatos E, Tsigkos S, Gounari P, Skrapari I, Gounaris T, Sioula E. An atypical presentation of visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with infliximab. J Clin Rheumatol. 2010, 16:38-9. 10.1097\/RHU.0b013e3181c8aa33","journal-title":"J Clin Rheumatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31823f0089","article-title":"Visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate","volume":"18","author":"Karagiannidis GS","year":"2012","unstructured":"Karagiannidis GS, Mantzourani M, Meletis J, Anastasopoulou AN, Vaiopoulos GA. Visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate. J Clin Rheumatol. 2012, 18:59. 10.1097\/RHU.0b013e31823f0089","journal-title":"J Clin Rheumatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.11.2011.5199","article-title":"Visceral leishmaniasis in immunosuppressed Caucasian patient","volume":"2012","author":"Toqeer M","year":"2012","unstructured":"Toqeer M, Rahman N, Whitehead MW, Lockwood D. Visceral leishmaniasis in immunosuppressed Caucasian patient. BMJ Case Rep. 2012, 2012:bcr1120115199. 10.1136\/bcr.11.2011.5199","journal-title":"BMJ Case Rep"},{"key":"ref33","article-title":"Viscerale leishmaniasis: niet alleen een tropische ziekte","volume":"157","author":"Cuperus FJ","year":"2013","unstructured":"Cuperus FJ, Oosterwijk PR, Vos A, et al.. Viscerale leishmaniasis: niet alleen een tropische ziekte. Ned Tijdschr Geneeskd. 2013, 157:5958.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.32.2.160","article-title":"A patient with rheumatoid arthritis under methotrexate and etanercept treatment presenting with fever and pancytopenia: an unexpected guest","volume":"32","author":"Patoulias D","year":"2021","unstructured":"Patoulias D, Papachristou S, Gouridou E, Stamou D, Chissan S, Bakatselos S. A patient with rheumatoid arthritis under methotrexate and etanercept treatment presenting with fever and pancytopenia: an unexpected guest. Mediterr J Rheumatol. 2021, 32:160-3. 10.31138\/mjr.32.2.160","journal-title":"Mediterr J Rheumatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1599381","article-title":"Case report: disseminated leishmaniasis and rheumatoid arthritis: navigating a clinical conundrum","volume":"16","author":"Shahini E","year":"2025","unstructured":"Shahini E, Marziliano D, Losito F, et al.. Case report: disseminated leishmaniasis and rheumatoid arthritis: navigating a clinical conundrum. Front Immunol. 2025, 16:1599381. 10.3389\/fimmu.2025.1599381","journal-title":"Front Immunol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1590\/S1678-9946202264021","article-title":"Severe visceral leishmaniasis and COVID-19 coinfection in an immunosuppressed patient","volume":"64","author":"Martins LP","year":"2022","unstructured":"Martins LP, Fukasawa JT, Messias MB, Castanho RE, Andrade LA, Speran\u00e7a MA, Suzuki RB. Severe visceral leishmaniasis and COVID-19 coinfection in an immunosuppressed patient. Rev Inst Trop Med S Paulo. 2022, 64:e21. 10.1590\/S1678-9946202264021","journal-title":"Rev Inst Trop Med S Paulo"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2016.07.005","article-title":"Visceral leishmaniasis in a rheumatoid arthritis patient receiving methotrexate","volume":"13","author":"Reina D","year":"2017","unstructured":"Reina D, Cerd\u00e0 D, G\u00fcell E, Mart\u00ednez Montauti J, Pineda A, Corominas H. Visceral leishmaniasis in a rheumatoid arthritis patient receiving methotrexate. Reumatol Clin. 2017, 13:354-6. 10.1016\/j.reuma.2016.07.005","journal-title":"Reumatol Clin"},{"key":"ref38","article-title":"Visceral leishmaniasis among immunosuppressed patients with rheumatic diseases","volume":"2010","author":"Erre GL","unstructured":"Erre GL, Mesina P, Tonelli N, Passiu G. Visceral leishmaniasis among immunosuppressed patients with rheumatic diseases. Clin Exp Rheumatol. 2010:590-1.","journal-title":"Clin Exp Rheumatol"},{"key":"ref39","article-title":"Felty\u2019s syndrome and Kala-azar: a challenge for the rheumatologist","volume":"50","author":"Viana RB","year":"2010","unstructured":"Viana RB, Neiva CLS, Dias AFM de P, et al.. Felty\u2019s syndrome and Kala-azar: a challenge for the rheumatologist. Rev Bras Reumatol. 2010, 50:","journal-title":"Rev Bras Reumatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2701","article-title":"A patient with rheumatoid arthritis, cryoglobulinaemia, and an \"accidental\" finding","volume":"348","author":"Liapis K","year":"2014","unstructured":"Liapis K, Chung Y, Akhtar W, Taussig D. A patient with rheumatoid arthritis, cryoglobulinaemia, and an \"accidental\" finding. BMJ. 2014, 348:g2701. 10.1136\/bmj.g2701","journal-title":"BMJ"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2571-x","article-title":"Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy","volume":"17","author":"Darcis G","year":"2017","unstructured":"Darcis G, Van der Auwera G, Giot JB, et al.. Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy. BMC Infect Dis. 2017, 17:478. 10.1186\/s12879-017-2571-x","journal-title":"BMC Infect Dis"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.5694\/mja12.11003","article-title":"Visceral leishmaniasis in a patient taking adalimumab for rheumatoid arthritis","volume":"198","author":"Berry CE","year":"2013","unstructured":"Berry CE, Tsai J, Tierney A, Pickles R. Visceral leishmaniasis in a patient taking adalimumab for rheumatoid arthritis. Med J Aust. 2013, 198:331-3. 10.5694\/mja12.11003","journal-title":"Med J Aust"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.01.006","article-title":"Leishmaniasis during anti-tumor necrosis factor therapy: report of 4 cases and review of the literature (additional 28 cases)","volume":"43","author":"Guedes-Barbosa LS","year":"2013","unstructured":"Guedes-Barbosa LS, Pereira da Costa I, Fernandes V, Henrique da Mota LM, de Menezes I, Aaron Scheinberg M. Leishmaniasis during anti-tumor necrosis factor therapy: report of 4 cases and review of the literature (additional 28 cases). Semin Arthritis Rheum. 2013, 43:152-7. 10.1016\/j.semarthrit.2013.01.006","journal-title":"Semin Arthritis Rheum"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s40794-019-0092-x","article-title":"Imported visceral leishmaniasis and immunosuppression in seven Norwegian patients","volume":"5","author":"Schwartz T","year":"2019","unstructured":"Schwartz T, Jensenius M, Blomberg B, Fladeby C, M\u00e6land A, Pettersen FO. Imported visceral leishmaniasis and immunosuppression in seven Norwegian patients. Trop Dis Travel Med Vaccines. 2019, 5:16. 10.1186\/s40794-019-0092-x","journal-title":"Trop Dis Travel Med Vaccines"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.4081\/idr.2016.6545","article-title":"Leishmania infantum and Epstein-Barr virus co-infection in a patient with hemophagocytosis","volume":"8","author":"Gaifer Z","year":"2016","unstructured":"Gaifer Z, Boulassel MR. Leishmania infantum and Epstein-Barr virus co-infection in a patient with hemophagocytosis. Infect Dis Rep. 2016, 8:6545. 10.4081\/idr.2016.6545","journal-title":"Infect Dis Rep"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.933012","article-title":"Hemophagocytic lymphohistiocytosis triggered by leishmaniasis: a case report and literature review","volume":"22","author":"Neycheva S","year":"2021","unstructured":"Neycheva S, Oparanov B, Kamburova A, Karalilova R, Stoeva V. Hemophagocytic lymphohistiocytosis triggered by leishmaniasis: a case report and literature review. Am J Case Rep. 2021, 22:e933012. 10.12659\/AJCR.933012","journal-title":"Am J Case Rep"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.17650\/1818-8346-2022-17-3-89-97","article-title":"Hemophagocytic syndrome associated with leishmaniasis: case report","volume":"17","author":"Potapenko VG","year":"2022","unstructured":"Potapenko VG, Antonov MM, Vinogradova NV, et al.. Hemophagocytic syndrome associated with leishmaniasis: case report. Oncohematology. 2022, 17:89-97. 10.17650\/1818-8346-2022-17-3-89-97","journal-title":"Oncohematology"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1663551","article-title":"Case report: fever of unknown origin with hemophagocytic lymphohistiocytosis and intestinal hemorrhage-a successfully treated case of severe visceral leishmaniasis","volume":"12","author":"Wang H","year":"2025","unstructured":"Wang H, Li J, Huang W. Case report: fever of unknown origin with hemophagocytic lymphohistiocytosis and intestinal hemorrhage-a successfully treated case of severe visceral leishmaniasis. Front Med. 2025, 12:1663551. 10.3389\/fmed.2025.1663551","journal-title":"Front Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1238405","article-title":"Felty's syndrome","volume":"10","author":"Wegscheider C","year":"2023","unstructured":"Wegscheider C, Ferincz V, Sch\u00f6ls K, Maieron A. Felty's syndrome. Front Med. 2023, 10:1238405. 10.3389\/fmed.2023.1238405","journal-title":"Front Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02941-3","article-title":"Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore","volume":"24","author":"Knaak C","year":"2020","unstructured":"Knaak C, Nyvlt P, Schuster FS, et al.. Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore. Crit Care. 2020, 24:244. 10.1186\/s13054-020-02941-3","journal-title":"Crit Care"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1111\/joim.20065","article-title":"Multicenter validation of secondary hemophagocytic lymphohistiocytosis diagnostic criteria","volume":"297","author":"Lachmann G","year":"2025","unstructured":"Lachmann G, Heeren P, Schuster FS, et al.. Multicenter validation of secondary hemophagocytic lymphohistiocytosis diagnostic criteria. J Intern Med. 2025, 297:312-27. 10.1111\/joim.20065","journal-title":"J Intern Med"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-026-12862-1","article-title":"Clinical spectrum and laboratory correlates of concurrent hemophagocytic lymphohistiocytosis and toxoplasmosis: a systematic review","volume":"26","author":"Shahini A","year":"2026","unstructured":"Shahini A, Javan ZH, Ghasemikhah R. Clinical spectrum and laboratory correlates of concurrent hemophagocytic lymphohistiocytosis and toxoplasmosis: a systematic review. BMC Infect Dis. 2026, 26:626. 10.1186\/s12879-026-12862-1","journal-title":"BMC Infect Dis"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.03.047","article-title":"Hemophagocytic lymphohistiocytosis in imported pediatric visceral leishmaniasis in a nonendemic area","volume":"165","author":"Bode SF","year":"2014","unstructured":"Bode SF, Bogdan C, Beutel K, et al.. Hemophagocytic lymphohistiocytosis in imported pediatric visceral leishmaniasis in a nonendemic area. J Pediatr. 2014, 165:147-153.e1. 10.1016\/j.jpeds.2014.03.047","journal-title":"J Pediatr"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00273-4","article-title":"Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline","volume":"6","author":"Cox MF","year":"2024","unstructured":"Cox MF, Mackenzie S, Low R, et al.. Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline. Lancet Rheumatol. 2024, 6:51-62. 10.1016\/S2665-9913(23)00273-4","journal-title":"Lancet Rheumatol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2008.02.013","article-title":"Visceral leishmaniasis associated hemophagocytic lymphohistiocytosis--case report and systematic review","volume":"56","author":"Rajagopala S","year":"2008","unstructured":"Rajagopala S, Dutta U, Chandra KS, Bhatia P, Varma N, Kochhar R. Visceral leishmaniasis associated hemophagocytic lymphohistiocytosis--case report and systematic review. J Infect. 2008, 56:381-8. 10.1016\/j.jinf.2008.02.013","journal-title":"J Infect"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-015-4801-8","article-title":"Specific K39 antibody response and its persistence after treatment in patients with imported leishmaniasis","volume":"115","author":"Reiter-Owona I","year":"2016","unstructured":"Reiter-Owona I, Rehkaemper-Schaefer C, Arriens S, Rosenstock P, Pfarr K, Hoerauf A. Specific K39 antibody response and its persistence after treatment in patients with imported leishmaniasis. Parasitol Res. 2016, 115:761-9. 10.1007\/s00436-015-4801-8","journal-title":"Parasitol Res"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.18-0617","article-title":"Case reports: late emergence of cutaneous leishmaniasis in an immunocompromised patient in a non-endemic setting","volume":"100","author":"New D","year":"2019","unstructured":"New D, Rogers BA. Case reports: late emergence of cutaneous leishmaniasis in an immunocompromised patient in a non-endemic setting. Am J Trop Med Hyg. 2019, 100:115-6. 10.4269\/ajtmh.18-0617","journal-title":"Am J Trop Med Hyg"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-\u03b1: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi T","year":"2010","unstructured":"Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-\u03b1: structure, function and interaction with anti-TNF agents. Rheumatology. 2010, 49:1215-28. 10.1093\/rheumatology\/keq031","journal-title":"Rheumatology"},{"key":"ref59","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2011-200596","article-title":"Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats","volume":"71","author":"Bogdan C","year":"2012","unstructured":"Bogdan C. Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats. Ann Rheum Dis. 2012, 71:i60-6.","journal-title":"Ann Rheum Dis"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007708","article-title":"Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression","volume":"13","author":"Bosch-Nicolau P","year":"2019","unstructured":"Bosch-Nicolau P, Ubals M, Salvador F, et al.. Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression. PLoS Negl Trop Dis. 2019, 13:e0007708. 10.1371\/journal.pntd.0007708","journal-title":"PLoS Negl Trop Dis"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjag067","article-title":"Risk of symptomatic leishmaniasis in patients with inflammatory bowel disease receiving biologic therapy in an endemic Mediterranean region: a population-based case-control study","volume":"20","author":"Gimeno-Pitarch L","year":"2026","unstructured":"Gimeno-Pitarch L, Iborra M, Crespo A, et al.. Risk of symptomatic leishmaniasis in patients with inflammatory bowel disease receiving biologic therapy in an endemic Mediterranean region: a population-based case-control study. J Crohns Colitis. 2026, 20:10.1093\/ecco-jcc\/jjag067","journal-title":"J Crohns Colitis"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03674.x","article-title":"Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe","volume":"18","author":"Zanger P","year":"2012","unstructured":"Zanger P, K\u00f6tter I, Kremsner PG, Gabrysch S. Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe. Clin Microbiol Infect. 2012, 18:670-6. 10.1111\/j.1469-0691.2011.03674.x","journal-title":"Clin Microbiol Infect"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/520582-haemophagocytic-lymphohistiocytosis-triggered-by-visceral-leishmaniasis-masquerading-as-epstein-barr-virus-ebv-associated-haemophagocytic-lymphohistiocytosis-in-rheumatoid-arthritis-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:31:20Z","timestamp":1789021880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/520582-haemophagocytic-lymphohistiocytosis-triggered-by-visceral-leishmaniasis-masquerading-as-epstein-barr-virus-ebv-associated-haemophagocytic-lymphohistiocytosis-in-rheumatoid-arthritis-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":62,"URL":"https:\/\/doi.org\/10.7759\/cureus.116027","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}